You are here

Primary tabs

Radiant Pain Relief
5
Login/Register to Rate

Summary

 

Successful Pain Treatment without Needles or Drugs

Safe, Consistently Effective Results

 

Radiant Pain Relief Centres

About Radiant

 

Radiant Pain Relief Centres offers a new way chronic pain is treated through its exclusive direct to consumer, clinical business built around a novel Patent Protected FDA-cleared device and a highly refined care model. Radiant’s business model is predicated on the establishment of systems designed to ensure consistency fundamental for building a disruptive business and a strong consumer brand.

With over 3 years of clinical operating experience and treating hundreds of patients with nearly every type of chronic page in a pilot operation, Radiant has proven the therapeutic benefits of the device with an 84% average reduction in pain and over 90% of patients concluding therapy at zero or near zero levels.

Radiant’s unique and progressive treatment for chronic pain helps retrain the brain and restore it back to a more normal, healthy perception of pain. Rather than masking the pain, Radiant’s novel technology safely and effectively retrains the brain restoring it back to a more normalized perception of pain. Treatment is safe, effective and side effect free, even when other treatments have failed, all while being delivered in comfortable, inviting, spa-like centers, rather than typical un-inspiring clinic settings.

Key Highlights

 

Accreditations

Other Highlights

  • 91.4% of all patients complete at zero or near in pain score
  • Technology tested and proven at: The Mayo Clinic and Johns Hopkins University
  • 20% of the world’s population presently suffers from chronic pain
  • Market growth of 3.7% CAGR over the period between 2016 and 2024

 

Research Facilities

 

Successful Pain Treatment without Needles or Drugs

Safe, Consistently Effective Results

 

Radiant Pain Relief Centres

About Radiant

 

Radiant Pain Relief Centres offers a new way chronic pain is treated through its exclusive direct to consumer, clinical business built around a novel Patent Protected FDA-cleared device and a highly refined care model. Radiant’s business model is predicated on the establishment of systems designed to ensure consistency fundamental for building a disruptive business and a strong consumer brand.

With over 3 years of clinical operating experience and treating hundreds of patients with nearly every type of chronic page in a pilot operation, Radiant has proven the therapeutic benefits of the device with an 84% average reduction in pain and over 90% of patients concluding therapy at zero or near zero levels.

Radiant’s unique and progressive treatment for chronic pain helps retrain the brain and restore it back to a more normal, healthy perception of pain. Rather than masking the pain, Radiant’s novel technology safely and effectively retrains the brain restoring it back to a more normalized perception of pain. Treatment is safe, effective and side effect free, even when other treatments have failed, all while being delivered in comfortable, inviting, spa-like centers, rather than typical un-inspiring clinic settings.

Key Highlights

 

Accreditations

Other Highlights

  • 91.4% of all patients complete at zero or near in pain score
  • Technology tested and proven at: The Mayo Clinic and Johns Hopkins University
  • 20% of the world’s population presently suffers from chronic pain
  • Market growth of 3.7% CAGR over the period between 2016 and 2024

 

Research Facilities

The Pain Epidemic

Over 100 million people suffer from chronic pain every year and the effects of pain exact a tremendous cost on our country in health care costs, rehabilitation and lost worker productivity, as well as the emotional and financial burden it places on patients and their families. According to the Institute of Medicine Report: Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research, pain is a significant public health problem that costs society at least $560-$635 billion annually, an amount equal to about $2,000.00 for everyone living in the US. This includes the total incremental cost of health care due to pain from ranging between $261 to $300 billion and $297-$336 billion due to lost productivity (based on days of work missed, hours of work lost, and lower wages).

Historical treatment solution for chronic pain, including drugs, needles, surgeries and the range of “alternative” solutions are often not effective at treating chronic pain with lasting results, and in many cases may be highly risky, addictive or dangerous. This is because chronic pain becomes a disease, rather than a symptom of another problem. Chronic pain is a pathological condition, a disease of its own, rather than a symptom of a problem. In most chronic pain, the brain develops an expectation and hypersensitivity to pain, causing it to grow in duration or intensity beyond what would be appropriate. Masking the pain with a drug, injection, or physical manipulation will often provide only temporary relief, but the side effects and risks of those treatments often contribute to other comorbidities, and health and societal problems, like the opioid addiction problem plaguing our country.

 

Current Pain Relief Options

  • Drugs
  • Injections
  • Surgery
  • Complementary & Alternative Medicine

Issues With Current Options

  • Largely ineffective
  • Temporary masking or dulling pain
  • Risky, addictive, dangerous
  • Invasive, costly
  • Not consistent or scalable

 

 

A New Technology in Pain Treatment

Safe, Consistently Effective Results Without Drugs, Needles or Surgery

The Technology & Care Model

With an FDA-510(k) clearance, Radiant’s Technology virtually re-trains the brain when it comes to the way it responds to pain. Electrodes are placed on the body in pairs, and the technology directs electrical signals to simulate non-pain information in patients. The technology acts like an artificial nerve as it generates a series of artificial impulses that mimic what exists in us naturally when we don’t have chronic pain

Since 2014 Radiant has had an exclusive license for an FDA-cleared technology known in the medical and FDA literature as Scrambler Therapy. Due to commercialization challenges encountered and created by the former licensee (including high cost of equipment, little or no insurance reimbursement, a fundamental misunderstanding of how the technology works, etc.), this technology has not found wide-spread adoption by the medical establishment. However, Radiant has an opportunity to prove and to commercialize the technology differently. Radiant’s business model is to build direct-to-consumer clinical centers. This controls the clinical and business operating variables to ensure consistency in result and experience necessary to build a strong brand. Additionally, this practice creates alignment and value across the entire supply chain all while costing patients a reasonable $10/day average for treatment. Through the Radiant model, this therapy becomes appealing and affordable to the consumer giving Radiant revenue to grow, expand, and to buy more equipment, thus benefiting everyone upstream in the supply chain.

Much like Tesla Motors has done with their novel, best in class electric cars, which are sold exclusively in their own Tesla owned retail stores rather than traditional car dealerships, Radiant’s direct-to-consumer clinical model is part of the disruptive solution, allowing for an improved patient experience that transcends the technology. By building and owning centers, Radiant will be able to capture much more revenue and generate much higher profits than through selling the equipment (particularly given the market constraints of high cost of equipment, little insurance reimbursement and other factors). While there are costs associated with opening new centres, Radiant creates efficiencies in the three biggest cost areas that make commercializing this novel technology much more viable:

Cost of personnel to deliver the care

Rather than using physicians or RNs to deliver the treatment, Radiant uses lower level medical technicians (typically LPNs) which they train and certify in very exacting protocols, and which are overseen by higher credentialed clinical staff and physicians, thus allowing the company to produce high-quality care consistently at a much-reduced cost. Furthermore, in the Radiant center model, one technician is treating two patients on two devices simultaneously when the start times are staggered by 30 minutes, thus allowing the personnel costs to be cut in half again, and creating margin in the operation that allows the therapy to be affordable, while still netting EBITDA margins north of 35%.

Cost of equipment

Radiant buys at a wholesale price much lower than retail cost

Cost of acquisition of new customers/patients

By owning the treatment centers, Radiant can create operating margins while keeping the price low, and maintain the necessary consistency to build a brand. In return, this creates an incentive to want to advertise and market. With multiple centers opened in the same market or geographical region, the high cost of retail advertising is spread across multiple centers, thus becoming more justifiable and creating a much stronger potential Return on Investment (ROI) from that marketing spend.

Today, Radiant has been able to secure complete North American rights to the next generation of technology. The US and global patents for this new, “next-gen” technology will be co-owned by Radiant, which will also exclusively hold the FDA-clearance. This evolution will put Radiant into a much stronger position to defend and evolve the intellectual property, even as it continues to build competitive barriers to entry through its first-to-market, patient-centered care model, and the development of the Radiant brand. As the company works through the steps of bringing this new technology to market, it continues to rely upon its current supply agreement allowing for no disruption to expansion in the short term. While new, competitive, technology may be developed, as Radiant becomes more established, grows a strong brand and captures more and more market share, it becomes a distribution source for that new technology rather than threatened by it. This is akin to building the railroad. Once the cost of laying the track has been achieved, revenues can flow unfettered across the track nearly indefinitely. The same is true with Radiant. By focus on the establishment of a strong brand, and expanded infrastructure of its centers, new technology is more likely to be met as an opportunity rather than a threat.

 

 

 

Types of Successfully Treated Pain

Growth Plan & Use of Proceeds

 

Radiant plans to raise sufficient capital to open 10-15 new Radiant Pain Relief Centres in diverse markets across the country. This will help establish Radiant’s solution nationally and build a strong brand. Radiant’s vision is to expand to hundreds of centers across the country over the coming years.

 

3-Year Plan

  • 2014-15: Pilot Center
  • 2016-17: First Full Center
  • 2018-19: Open 10-15 additional Centers
  • 2020+: Open 90+ additional Centers

 

Meet the Radiant Team

P. Brendon Lundberg

President/CEO

Over a decade of relevant leadership, sales, marketing & operations experience in healthcare, with several growth award winning companies. BSB/Marketing; MBA

 

David Farley, MD

Chief Medical Officer

Harvard/MIT trained physician with several decades of clinical care experience

 

Chris Roberts

COO/CFO

Portland Business Journal CFO of year 2009. CFO of Inc. Magazine and Portland Business Journal growth award winning healthcare consulting company. BBA/Accounting & Finance

 

Meet the Radiant Advisors

Advisory Board

Wallace A. Glausi, Esq.

A partner at AterWynne, with nearly 20 years experience forming and helping to capitalize over 200 different companies

Philip H Lundberg, PhD

An experienced healthcare, higher-education and international training and development professional with a particular expertise in building high-performing teams and productive company cultures

David Scott, CPA

An experienced and well respected CPA and long-time angel investor

Science Advisory Board

Charles Loprinzi, MD.

Regis Professor of Breast Cancer Research, Mayo Clinic

Thomas Smith, MD

The Harry J. Duffey Family Professor of Palliative Medicine, Johns Hopkins

David B. Farley, MD

Medical Director: Harvard/MIT trained physician with several decades of clinical care experience

Board of Directors:

P. Brendon Lundberg, CEO

Over a decade of relevant leadership, sales, marketing & operations experience in healthcare, with several growth award winning companies. BSB/Marketing; MBA

Edward Brennan, PhD

Chairman of the Board: An experienced C-level medical device executive with a PhD in biochemistry and a background in venture capital

Thomas Rota – Directors

A career CFO consultant with decades of financial leadership in building companies and taking companies public

aws
aff

NO MONEY OR OTHER CONSIDERATION IS BEING SOLICITED, AND IF SENT IN RESPONSE, WILL NOT BE ACCEPTED. NO OFFER TO BUY THE SECURITIES CAN BE ACCEPTED AND NO PART OF THE PURCHASE PRICE CAN BE RECEIVED UNTIL THE OFFERING STATEMENT FILED BY THE COMPANY WITH THE SEC HAS BEEN QUALIFIED BY THE SEC. ANY SUCH OFFER MAY BE WITHDRAWN OR REVOKED, WITHOUT OBLIGATION OR COMMITMENT OF ANY KIND, AT ANY TIME BEFORE NOTICE OF ACCEPTANCE GIVEN AFTER THE DATE OF QUALIFICATION. AN INDICATION OF INTEREST INVOLVES NO OBLIGATION OR COMMITMENT OF ANY KIND. AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION (SEC). YOU MAY OBTAIN A COPY OF THE PRELIMINARY OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT FROM: Click here THE COMPANY IS “TESTING THE WATERS” UNDER REGULATION A UNDER THE SECURITIES ACT OF 1933. THIS PROCESS ALLOWS COMPANIES TO DETERMINE WHETHER THERE MAY BE INTEREST IN AN EVENTUAL OFFERING OF ITS SECURITIES. THE COMPANY IS NOT UNDER ANY OBLIGATION TO MAKE AN OFFERING UNDER REGULATION A. IT MAY CHOOSE TO MAKE AN OFFERING TO SOME, BUT NOT ALL, OF THE PEOPLE WHO INDICATE AN INTEREST IN INVESTING, AND THAT OFFERING MIGHT NOT BE MADE UNDER REGULATION A. IF THE COMPANY DOES GO AHEAD WITH AN OFFERING, IT WILL ONLY BE ABLE TO MAKE SALES AFTER IT HAS FILED AN OFFERING STATEMENT WITH THE SECURITIES AND EXCHANGE COMMISSION (SEC) AND THE SEC HAS “QUALIFIED” THE OFFERING STATEMENT. THE INFORMATION IN THAT OFFERING STATEMENT WILL BE MORE COMPLETE THAN THE INFORMATION THE COMPANY IS PROVIDING NOW, AND COULD DIFFER IN IMPORTANT WAYS. YOU MUST READ THE DOCUMENTS FILED WITH THE SEC BEFORE INVESTING. THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.